other material
confidence high
sentiment negative
materiality 0.75
Veru refocuses on sabizabulin for COVID/influenza; terminates prostate cancer trial, pauses two assets
VERU INC.
- Terminating Phase 3 VERACITY trial of sabizabulin in prostate cancer; pausing Phase 2 Veru-100 and zuclomiphene development.
- Plans Phase 3 confirmatory study of sabizabulin for hospitalized moderate/severe COVID-19 patients at high risk for ARDS.
- Plans Phase 3 study of sabizabulin for hospitalized influenza patients at high risk for ARDS.
- Updated Phase 3 ENABLAR-2 study of enobosarm + abemaciclib for second-line metastatic breast cancer; rolling ARTEST into it pending FDA/Lilly approval.
- Cash conservation measures including personnel reduction; prior FDA denial of EUA for sabizabulin on March 2, 2023.